>

Gardasil 9 Vaccine 0.5ml Injection Syringe

Gardasil SKU: 54406

Gardasil 9 Vaccine 0.5ml Injection Syringe

Gardasil SKU: 54406
/
  • Netherlands
  • In Stock
  • Inventory on the way
A vaccine administered by injection to protect against diseases. The vaccine is intended for children, adolescents, and adults from 9 years of age and does not treat existing HPV infections.

Indications:
- Prevention of cervical, vulvar, and vaginal cancers associated with HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58.
- Prevention of anal cancers and pre-cancerous lesions associated with HPV.
- Prevention of genital warts in males and females caused by HPV types 6 and 11.

Main Active Ingredients:
- Human Papillomavirus Type 6 L1 protein 30 micrograms.
- Human Papillomavirus Type 11 L1 protein 40 micrograms.
- Human Papillomavirus Type 16 L1 protein 60 micrograms.
- Human Papillomavirus Type 18 L1 protein 40 micrograms.
- Human Papillomavirus Type 31 L1 protein 20 micrograms.
- Human Papillomavirus Type 33 L1 protein 20 micrograms.
- Human Papillomavirus Type 45 L1 protein 20 micrograms.
- Human Papillomavirus Type 52 L1 protein 20 micrograms.
- Human Papillomavirus Type 58 L1 protein 20 micrograms.

Precautions:
- Do not administer if allergic to any of the active substances or other ingredients.
- Inform your doctor if you have a bleeding disorder or a weakened immune system.
- Delay vaccination in case of moderate or severe acute illness or high fever.
- Vaccination may not fully protect all recipients; continue appropriate preventive measures.
- Pregnant individuals should postpone vaccination until after pregnancy.

Side Effects:
- Pain, swelling, or redness at the injection site.
- Headache.
- Bruising or itching at the injection site.
- Fever.
- Tiredness or unusual fatigue.
- Dizziness.
- Nausea.
- Swollen glands (neck, armpit, or groin).
- Hives (urticaria).
- Fainting, sometimes accompanied by shaking or stiffening.
- Vomiting.
- Joint or muscle pain.
- Chills or generally feeling unwell.
- Lump (nodule) at the injection site.

Drug-Drug Interactions:
- Gardasil 9 can be co-administered with dTap, dT-IPV, or dTap-IPV vaccines at a separate injection site.
- Immunosuppressive medicines may reduce vaccine effectiveness.

- Gardasil 9 is administered intramuscularly, preferably into the deltoid area of the upper arm or the higher anterolateral thigh.
- For individuals 9–14 years old, a 2-dose schedule is recommended, with the second dose given 5–13 months after the first.
- If starting at 15 years or older, a 3-dose schedule is required: second dose 2 months after the first and third dose 6 months after the first.
- Shake the pre-filled syringe well before use and inspect the suspension for particulate matter or discoloration.
- Use the entire recommended dose.

  • Anti-viral

Human Papillomavirus Type 6 L1 protein, Human Papillomavirus Type 11 L1 protein, Human Papillomavirus Type 16 L1 protein, Human Papillomavirus Type 18 L1 protein, Human Papillomavirus Type 31 L1 protein, Human Papillomavirus Type 33 L1 protein, Human Papillomavirus Type 45 L1 protein, Human Papillomavirus Type 52 L1 protein, Human Papillomavirus Type 58 L1 protein, Amorphous aluminium hydroxyphosphate sulfate, Sodium chloride, Histidine, Polysorbate 80 (E433), Borax (E285), Water for injections.

Recently Viewed